Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Sold by JPMorgan Chase & Co.

JPMorgan Chase & Co. decreased its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 24.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 304,334 shares of the company’s stock after selling 96,017 shares during the quarter. JPMorgan Chase & Co. owned about 0.38% of Viridian Therapeutics worth $5,834,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. R Squared Ltd acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at $26,000. AlphaQuest LLC grew its stake in Viridian Therapeutics by 119.0% during the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company’s stock valued at $54,000 after purchasing an additional 1,519 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of Viridian Therapeutics in the fourth quarter valued at about $164,000. KLP Kapitalforvaltning AS purchased a new position in shares of Viridian Therapeutics in the fourth quarter worth about $219,000. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth about $235,000.

Analyst Upgrades and Downgrades

VRDN has been the topic of several research reports. Needham & Company LLC reiterated a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Wells Fargo & Company reissued an “equal weight” rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Stock Performance

Shares of VRDN stock opened at $13.13 on Friday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The business’s 50 day moving average is $14.65 and its two-hundred day moving average is $18.69. The company has a market capitalization of $1.07 billion, a P/E ratio of -3.05 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.24. The firm had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.05 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. Analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.